Table 1.
Newborns, n = 100 | ||||
Gender: Male (%) | 56.0% | |||
Birth weight (g), mean ± standard deviation (SD), (range) | 3427 ± 455 (2140–4960) | |||
≤15th percentile | 15% | |||
≥85th percentile | 14% | |||
Mothers, n = 100 | ||||
Age (years), mean ± SD (range) | 27.7 ± 5.3 (18–41) | |||
Vaginal birth (induction with oxytocin) | 39% (21 from 100) | |||
First pregnancy | 60% | |||
First delivery | 62% | |||
Antibiotic therapy during pregnancy | 30% | |||
Antibiotic therapy during childbirth * (prevention of GBS infection) |
81% (20%) | |||
Median (range) increase in BMI during pregnancy | 5.7 (0.58–11.2) | |||
A. Categories: BMI before pregnancy | <18.5 | ≤18.5 <25 | ≥25 <30) | ≥30 |
Percent within each BMI category A. | 12% | 56% | 20% | 12% (12%) |
B. Categories: BMI before childbirth | <18.5 | ≤18.5 <25 | ≥25 <30 | ≥30 |
Percent within each BMI category B. | 0% | 16% | 36% | 48% (48%) |
C. Categories: Weight gain during pregnancy | <12 kg | 12–18 kg | >18 kg | |
Percent in each weight gain category C. | 25% | 39% | 36% |
BMI: Body Mass Index; *: half an hour before Caesarean section, a woman received intravenous cefazolin at a dose of 2 g. If cervical colonization of Streptococcus agalactiae was found or with lack of evidence of no colonization, women received intravenous ampicillin at 2 g which was repeated every 4 h until the child was born.